UNDERWRITING AGREEMENTUnderwriting Agreement • January 12th, 2018 • Menlo Therapeutics, Inc. • Pharmaceutical preparations • New York
Introductory. Menlo Therapeutics Inc., a Delaware corporation (the “Company”), proposes to issue and sell to the several underwriters named in Schedule A (the “Underwriters”) an aggregate of shares of its common stock, par value $ per share (the “Shares”). The Shares to be sold by the Company are called the “Firm Shares.” In addition, the Company has granted to the Underwriters an option to purchase up to an additional Shares as provided in Section 2. The additional Shares to be sold by the Company pursuant to such option are collectively called the “Optional Shares.” The Firm Shares and, if and to the extent such option is exercised, the Optional Shares, are collectively called the “Offered Shares.” Jefferies LLC (“Jefferies”), Piper Jaffray & Co (“Piper Jaffray”) and Guggenheim Securities LLC (“Guggenheim”) have agreed to act as representatives of the several Underwriters (in such capacity, the “Representatives”) in connection with the offering and sale of the Offered Shares. To the
